Long-term consequences of ovarian ablation for premenopausal breast cancer.

e11559 Background: According to the SOFT/TEXT trials, an aromatase inhibitor (AI) with ovarian ablation (OA) is associated with a higher 5-year disease-free survival than tamoxifen, with or without OA, in premenopausal women with ER+ early breast cancer. However, the long-term effects and costs of OA have not been evaluated. When OA is done by oophorectomy, there are long-term health consequences from premature menopause such as osteoporosis and coronary heart disease, which may occur many years later. The objective was to conduct a cost-effectiveness analysis comparing tamoxifen alone to OA with tamoxifen or OA with AI in premenopausal women. Methods: A Markov Monte Carlo simulation model estimated the costs and benefits of 3 adjuvant treatment strategies for ER+ early breast cancer in premenopausal women. Effectiveness was measured in average life expectancy gain (years), while costs were averaged over a lifetime (USD 2015). Primary outcome measure was the incremental cost-effectiveness ratio (ICER). Mo...